Torin 1

Catalog No.S2827

Molecular Weight(MW): 607.62

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

5 Customer Reviews

Huh-7.5 cells were treated with increasing concentration of Torin 1, a known autophagy inducer, and the autophagy response was assessed by measuring LC3II and p62 levels.

Am J Pathol 2014 184(1), 214-29. Torin 1 purchased from Selleck.

Flag-tagged SENP3 was immunoprecipitated from HeLa cells and used for in vitro phosphorylation assay with [32P]ATP with either the mock-treated or Torin1-treated mTOR/Raptor/MLST8 complex. (Upper) The samples then were subjected to SDS-PAGE, followed by autoradiography. mTOR autophosphorylation is indicated by an asterisk. (Lower) Immunopurified SENP3 was monitored by Western blotting with anti-Flag antibody.

Mol Cell Biol 2014 34(24), 4474-84. Torin 1 purchased from Selleck.
Exp Cell Res, 2018, 363(1):84-94. Torin 1 purchased from Selleck.

Representative Western blots showing LC3 in PP242 (PP) or Torin1 (Tor) treated HepG2 cells. HepG2 cells were treated with 10 uM PP242 or 0.1 uM Torin1 for 24 h.

Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.05.047. Torin 1 purchased from Selleck.
Bone marrow derived macrophages were pre-treated with 10nM Torin 1 for 1h prior to LPS treatment (100 ng/ml). TNF-a production was analyzed 24h later.

Lim Hsiu Kim, Lina from National University of Singapore. Torin 1 purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description

Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

Targets

mTORC1 ^[1] (Cell-free assay)	mTOR ^[2] (Cell-free assay)	DNA-PK ^[2] (Cell-free assay)	mTORC2 ^[1] (Cell-free assay)	p110γ ^[2] (Cell-free assay)	View More
2 nM	4.32 nM	6.34 nM	10 nM	171 nM	View More

In vitro

Torin1 inhibits phosphorylation of mTORC1 and mTORC2 substrates in cells at concentrations of 2 and 10 nM, respectively. Moreover, Torin1 exhibits 1000-fold selectivity for mTOR over PI3K (EC50 = 1800 nM) and exhibits 100-fold binding selectivity relative to 450 other protein kinases. ^[1] ^[2] Torin1 causes cell cycle arrest through a rapamycin-resistant mechanism that is also independent of mTORC2. Torin1 disrupts mTORC1-dependent phenotypes more completely than rapamycin. Rapamycin-resistant functions of mTORC1 are required for cap-dependent translation. ^[1] In a recent study, it is reported Torin1 increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
ETK-1	M2\rfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nMcGlEPTB;MD6wNFA{ODZizszN	NFnaNVJUSU6JRWK=
OCUB-M	NHLjcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPPc5hGUUN3ME2wMlAxOTl2IN88US=>	NFTpZVlUSU6JRWK=
DOHH-2	NUC1cll1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMECyNlUh\|ryP	M{PN[HNCVkeHUh?=
NOS-1	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMECyOFIh\|ryP	NX3EVJU5W0GQR1XS
L-363	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\ybVBHUUN3ME2wMlAxOjh2IN88US=>	Ml7KV2FPT0WU
RL95-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMECzNkDPxE1?	M13RRXNCVkeHUh?=
BL-70	MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DaRWlEPTB;MD6wNFM{PyEQvF2=	MmfpV2FPT0WU
TGBC1TKB	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHyzSFFKSzVyPUCuNFA{PzlizszN	NWm4cGRRW0GQR1XS
697	M{nvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fWU2lEPTB;MD6wNFY{PCEQvF2=	MmnRV2FPT0WU
RPMI-8226	NF;FeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnjVoJKSzVyPUCuNFA3PTFizszN	MkfKV2FPT0WU
BL-41	MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfvTWM2OD1yLkCwOlk3KM7:TR?=	M{fDWXNCVkeHUh?=
MRK-nu-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwMEC3NFch\|ryP	M{HtWHNCVkeHUh?=
EW-1	MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUK1U4lVUUN3ME2wMlAxPzR7IN88US=>	MVfTRW5ITVJ?
EVSA-T	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYru[IREUUN3ME2wMlAxQDl{IN88US=>	MYTTRW5ITVJ?
HUTU-80	NFfuWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMEC5Nlkh\|ryP	MWHTRW5ITVJ?
VA-ES-BJ	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPBRmhLUUN3ME2wMlAxQTh2IN88US=>	MYXTRW5ITVJ?
GCIY	Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnO4TWM2OD1yLkCxNFA4KM7:TR?=	Ml\KV2FPT0WU
ES6	Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2D3dWlEPTB;MD6wNVA5OyEQvF2=	MWrTRW5ITVJ?
NALM-6	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjRTWM2OD1yLkCxNVAzKM7:TR?=	NFnsbWpUSU6JRWK=
LB996-RCC	M{G3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1K5fWlEPTB;MD6wNVE{PyEQvF2=	Mn7PV2FPT0WU
EW-16	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMEGxPVIh\|ryP	MmfwV2FPT0WU
KALS-1	M{e1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DY[GlEPTB;MD6wNVE6QCEQvF2=	NE\VW5lUSU6JRWK=
OPM-2	M4nGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fWTWlEPTB;MD6wNVI6KM7:TR?=	NXzmcW5GW0GQR1XS
KU812	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfvNI5KSzVyPUCuNFEzQTZizszN	MWnTRW5ITVJ?
A4-Fuk	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PoZWlEPTB;MD6wNVMyQSEQvF2=	NVTBfnZnW0GQR1XS
KGN	NITtR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfuTWM2OD1yLkCxN\|U6KM7:TR?=	MnrDV2FPT0WU
KS-1	NWG3W4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPZTWM2OD1yLkCxN\|kzKM7:TR?=	MlnaV2FPT0WU
no-11	NHjsV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmW0TWM2OD1yLkCxN\|k2KM7:TR?=	MXvTRW5ITVJ?
PSN1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkS5TWM2OD1yLkCxOFA6KM7:TR?=	MlTHV2FPT0WU
SK-LMS-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUezPXk6UUN3ME2wMlAyPDF\|IN88US=>	NXLZTWVqW0GQR1XS
LS-411N	M{fl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jwV2lEPTB;MD6wNVQ{QSEQvF2=	NULUZ5JEW0GQR1XS
HT-144	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMEG0OVEh\|ryP	MXPTRW5ITVJ?
ACN	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVz4RWxTUUN3ME2wMlAyPSEQvF2=	MXTTRW5ITVJ?
RKO	M{f6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\LTWM2OD1yLkCxOVM{KM7:TR?=	M13JWnNCVkeHUh?=
CMK	NXrWfXpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3n4b2lEPTB;MD6wNVU1OyEQvF2=	MoC4V2FPT0WU
GB-1	MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17ENGlEPTB;MD6wNVU2OyEQvF2=	NFvTbHJUSU6JRWK=
KE-37	NYPNdWY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTBwMEG1O\|Mh\|ryP	M1\UfnNCVkeHUh?=
no-10	NF7NfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\QTWM2OD1yLkCxOVg1KM7:TR?=	NYKzOYxuW0GQR1XS
MOLT-16	NHGwbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzvRXJKSzVyPUCuNFE3OjJizszN	NGm4eY5USU6JRWK=
HEL	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLsVHp6UUN3ME2wMlAyPjRizszN	NEOyToRUSU6JRWK=
NCI-H1355	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLSTWM2OD1yLkCxOlQ3KM7:TR?=	M2PXPXNCVkeHUh?=
IST-MEL1	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP2TWM2OD1yLkCxO\|c1KM7:TR?=	NGf3eHdUSU6JRWK=
MHH-PREB-1	Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMEG4NVgh\|ryP	MlHkV2FPT0WU
ES8	NV;tN\|MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF[2eW5KSzVyPUCuNFE5PDRizszN	M1PadHNCVkeHUh?=
LC-2-ad	NVHpUYVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnFTWM2OD1yLkCyNVM4KM7:TR?=	NHr2N4hUSU6JRWK=
LAMA-84	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMEKxOlch\|ryP	MoPXV2FPT0WU
BV-173	M{jiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PxSGlEPTB;MD6wNlIxOyEQvF2=	MmS2V2FPT0WU
SW872	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFq4T4hKSzVyPUCuNFIzPDdizszN	MVzTRW5ITVJ?
SK-UT-1	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHCd454UUN3ME2wMlAzOjZzIN88US=>	MYHTRW5ITVJ?
OS-RC-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPOTWM2OD1yLkCyN\|I{KM7:TR?=	NVfLeWNEW0GQR1XS
NCI-H747	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7hc\|JKSzVyPUCuNFI{OyEQvF2=	Mk\LV2FPT0WU
MZ2-MEL	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYW1XZZuUUN3ME2wMlAzOzN5IN88US=>	NV7vfYJyW0GQR1XS
TE-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfIbWl2UUN3ME2wMlAzOzd{IN88US=>	MnPzV2FPT0WU
KURAMOCHI	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLwSml[UUN3ME2wMlAzPDF2IN88US=>	NHX2R4NUSU6JRWK=
HD-MY-Z	M{D3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMEK0NlYh\|ryP	NWDMdIhWW0GQR1XS
GI-1	NHi3O\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMEK0Olkh\|ryP	NIf3XmhUSU6JRWK=
LB1047-RCC	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3DWVRrUUN3ME2wMlAzPDh6IN88US=>	MX7TRW5ITVJ?
TE-12	NY\zUoh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LpWGlEPTB;MD6wNlU2KM7:TR?=	M3K2ZnNCVkeHUh?=
MZ7-mel	NVO2NZM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HxU2lEPTB;MD6wNlYxQSEQvF2=	NHvZOmNUSU6JRWK=
MMAC-SF	M2\sTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml25TWM2OD1yLkCyOlM{KM7:TR?=	M{D5WXNCVkeHUh?=
A101D	NVn1NXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYCyUXBbUUN3ME2wMlAzPjVizszN	MX\TRW5ITVJ?
GR-ST	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1f2cWlEPTB;MD6wNlY2PSEQvF2=	M1TDZ3NCVkeHUh?=
MC116	M4XJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\BR5VKSzVyPUCuNFI3QCEQvF2=	M2P1NnNCVkeHUh?=
Ramos-2G6-4C10	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7YTWM2OD1yLkCyO\|Uh\|ryP	M{LZXnNCVkeHUh?=
ATN-1	NHLCeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYT6XlVNUUN3ME2wMlAzPzh7IN88US=>	MkiwV2FPT0WU
MFH-ino	MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMEK4NVIh\|ryP	NV7uNYV6W0GQR1XS
DEL	NHjRSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXW1WopEUUN3ME2wMlAzQDF3IN88US=>	M3;O[3NCVkeHUh?=
OCI-AML2	NEDqeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknlTWM2OD1yLkCyPFcyKM7:TR?=	MnXvV2FPT0WU
LXF-289	M1Pnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHU[XJKSzVyPUCuNFI5PzJizszN	NXjZc4REW0GQR1XS
IA-LM	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjRTWM2OD1yLkCyPVE4KM7:TR?=	Mn\SV2FPT0WU
EoL-1-cell	NX;hfIRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2Sx[GlEPTB;MD6wNlk6PiEQvF2=	NXL0[GZRW0GQR1XS
OVCAR-4	NWPW[GptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\5NpFKSzVyPUCuNFMxQTRizszN	MoLYV2FPT0WU
ES1	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIj6O5JKSzVyPUCuNFMxQTdizszN	NYj6dIJ1W0GQR1XS
CESS	NXrzdWZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrZU3dKSzVyPUCuNFMxQTlizszN	M33SPHNCVkeHUh?=
GAK	M{\1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzCSnRKSzVyPUCuNFMyQDZizszN	MVXTRW5ITVJ?
NTERA-S-cl-D1	MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\lW\|FKSzVyPUCuNFMzOjZizszN	NIrZbGhUSU6JRWK=
TE-10	Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LTOWlEPTB;MD6wN\|MyOSEQvF2=	NVPmcW5xW0GQR1XS
CCRF-CEM	NVLVcplwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHq3UppKSzVyPUCuNFM{PzFizszN	MmjuV2FPT0WU
NMC-G1	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljJTWM2OD1yLkCzOFQ5KM7:TR?=	NHP2bJhUSU6JRWK=
HOP-62	NV7LV5JFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\yVmJqUUN3ME2wMlA{PTV4IN88US=>	M4HoNnNCVkeHUh?=
SH-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWS3O204UUN3ME2wMlA{PTh{IN88US=>	MX;TRW5ITVJ?
NCI-H1648	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHy0cIpKSzVyPUCuNFM3OjJizszN	NFnYTFlUSU6JRWK=
EB-3	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVW0[GJPUUN3ME2wMlA{PjR\|IN88US=>	NFfpTJhUSU6JRWK=
BB65-RCC	M2PMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDvS2RKSzVyPUCuNFM3QTFizszN	M4XvfHNCVkeHUh?=
BE-13	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlf5TWM2OD1yLkCzO\|U6KM7:TR?=	NF21ZZRUSU6JRWK=
CP67-MEL	MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwMEO3OVkh\|ryP	NEDVZnhUSU6JRWK=
SW954	M1zDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMEO3PUDPxE1?	NHuyRWhUSU6JRWK=
TE-5	MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjHTWM2OD1yLkCzPFU1KM7:TR?=	NY\1V5FvW0GQR1XS
HCE-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjTXWdKSzVyPUCuNFM5PTVizszN	MoX4V2FPT0WU
LC-1F	NWjmXZJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\OTWM2OD1yLkCzPVg6KM7:TR?=	M{nT[3NCVkeHUh?=
TK10	NEjaOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHoTWM2OD1yLkC0NFE6KM7:TR?=	M3Oyc3NCVkeHUh?=
SJSA-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPzTWM2OD1yLkC0NVg5KM7:TR?=	NUnMe3d5W0GQR1XS
Daudi	MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInFNItKSzVyPUCuNFQzOjVizszN	MknlV2FPT0WU
SW982	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\oTWM2OD1yLkC0NlQ3KM7:TR?=	M1\ERnNCVkeHUh?=
SF126	NHrxVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfuTY8yUUN3ME2wMlA1OzZzIN88US=>	M1vCSHNCVkeHUh?=
TE-15	NInOO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMES0N\|Uh\|ryP	MVvTRW5ITVJ?
COLO-684	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGexTVBKSzVyPUCuNFQ2PjFizszN	NEnKXnhUSU6JRWK=
8-MG-BA	NIH2b\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1u5bGlEPTB;MD6wOFYzQSEQvF2=	NVHSWplKW0GQR1XS
NB13	M{HCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jHb2lEPTB;MD6wOFc4PiEQvF2=	NFfTPGdUSU6JRWK=
HCC1599	NXPvS\|B1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2m5T2lEPTB;MD6wOFg4QSEQvF2=	Mme4V2FPT0WU
SK-PN-DW	NX2xS3pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTrTWM2OD1yLkC0PVQ6KM7:TR?=	NGL3T49USU6JRWK=
ALL-PO	M2DYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEe5Z3hKSzVyPUCuNFQ6PTZizszN	NF7NUoVUSU6JRWK=
NB6	M1v6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzyWWNqUUN3ME2wMlA2OjdzIN88US=>	MWXTRW5ITVJ?
IST-SL2	NH\TOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r1SWlEPTB;MD6wOVM3OiEQvF2=	M{D3S3NCVkeHUh?=
BB30-HNC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMEW3N{DPxE1?	NGHrbolUSU6JRWK=
SW962	M2C5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7icFRKSzVyPUCuNFU4PjNizszN	M3PKWXNCVkeHUh?=
TGBC24TKB	NWPWbW0{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjCTWM2OD1yLkC1O\|k6KM7:TR?=	M13rS3NCVkeHUh?=
KINGS-1	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnWc49KSzVyPUCuNFU5ODNizszN	NWS0VldTW0GQR1XS
HC-1	MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rZUWlEPTB;MD6wOVgzPyEQvF2=	MoruV2FPT0WU
RS4-11	M33FSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUGxVIc2UUN3ME2wMlA2QTN6IN88US=>	NHPHUIlUSU6JRWK=
LS-123	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV31eVhjUUN3ME2wMlA2QTR{IN88US=>	MnrPV2FPT0WU
A3-KAW	NV7rXGlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1q2ZmlEPTB;MD6wOlIzPSEQvF2=	MWfTRW5ITVJ?
SNB75	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPBb3VKSzVyPUCuNFY{PDFizszN	MWXTRW5ITVJ?
SR	NUXyS\|dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvmTWM2OD1yLkC2N\|c1KM7:TR?=	NE\D[FFUSU6JRWK=
LOUCY	NIrwSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfCXZpKSzVyPUCuNFY{QTRizszN	NVnwOJp2W0GQR1XS
K5	NXvKdJpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfUfo46UUN3ME2wMlA3PDB\|IN88US=>	NWP6c\|lqW0GQR1XS
Becker	NV3ZTFFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7NW4hKSzVyPUCuNFY1OiEQvF2=	NYjmd29vW0GQR1XS
CTV-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jvVGlEPTB;MD6wOlU1QCEQvF2=	MYLTRW5ITVJ?
KLE	NFu4PZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrING1vUUN3ME2wMlA3PTh2IN88US=>	MnS1V2FPT0WU
MZ1-PC	NWfZfJZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHrenhKSzVyPUCuNFY2QThizszN	M4K4SXNCVkeHUh?=
MOLT-4	MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XFcmlEPTB;MD6wOlYxPSEQvF2=	NU\1d3pDW0GQR1XS
MLMA	Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF:0XGJKSzVyPUCuNFY4QCEQvF2=	M{\0cHNCVkeHUh?=
A388	M{DKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjJTVNyUUN3ME2wMlA3QDl\|IN88US=>	MoixV2FPT0WU
MV-4-11	NIK0R5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDGd5JWUUN3ME2wMlA3QTl3IN88US=>	Mlq0V2FPT0WU
DSH1	NHWwWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXqxTlloUUN3ME2wMlA4OTd\|IN88US=>	NVniWWJUW0GQR1XS
MONO-MAC-6	NISwW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzPNJVRUUN3ME2wMlA4OjF{IN88US=>	MmnjV2FPT0WU
ARH-77	M{WxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMEeyO\|gh\|ryP	MnqwV2FPT0WU
LB771-HNC	M{G5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMEe1OFkh\|ryP	NXv2VlBqW0GQR1XS
PF-382	MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonCTWM2OD1yLkC3OVY6KM7:TR?=	NHK0WZhUSU6JRWK=
KM12	NHH3XWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2CwU2lEPTB;MD6wO\|Y1KM7:TR?=	MWDTRW5ITVJ?
HAL-01	MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMEe2OVgh\|ryP	MmLVV2FPT0WU
RPMI-8402	NVrkc4dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkT0TWM2OD1yLkC3O\|g6KM7:TR?=	NXjXfWZiW0GQR1XS
OMC-1	M2K0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGWwfGVKSzVyPUCuNFc5ODRizszN	NX\NRYlRW0GQR1XS
HT	M1jhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWC2ZYxiUUN3ME2wMlA5KM7:TR?=	NU\ZeIRLW0GQR1XS
QIMR-WIL	NVXhbZRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TmZWlEPTB;MD6wPFA2PSEQvF2=	NWG3TYh3W0GQR1XS
KNS-42	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfOO3BKSzVyPUCuNFgzODNizszN	MYDTRW5ITVJ?
BC-3	M3nrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvUR2JUUUN3ME2wMlA5OjB2IN88US=>	NY[xZYhVW0GQR1XS
ES4	M{Hvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwMEiyPVYh\|ryP	MVPTRW5ITVJ?
NCI-H23	M3rtfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYC1N\|R5UUN3ME2wMlA5PDRizszN	NW[2cnhxW0GQR1XS
LB2518-MEL	NX3uUGtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXETWM2OD1yLkC4Olk3KM7:TR?=	MlWxV2FPT0WU
LC4-1	M4T6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjFTWM2OD1yLkC4O\|M5KM7:TR?=	NUjkdYw5W0GQR1XS
SIG-M5	NITMRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LkRmlEPTB;MD6wPFkxPCEQvF2=	M2rFcXNCVkeHUh?=
LP-1	NEjaRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3mzVGlEPTB;MD6wPFk{QCEQvF2=	M3rIZnNCVkeHUh?=
TE-8	NGmxS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMEmwNVYh\|ryP	NVLU[VU1W0GQR1XS
K-562	M1jCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoO3TWM2OD1yLkC5NVIh\|ryP	M1L3fXNCVkeHUh?=
J-RT3-T3-5	NGfDNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnxWXFyUUN3ME2wMlA6OTV\|IN88US=>	MlK3V2FPT0WU
DU-4475	NXfs[YhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrzTXVKSzVyPUCuNFkyPjVizszN	MUfTRW5ITVJ?
RXF393	NYjZPWJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYC3e25FUUN3ME2wMlA6PDZ{IN88US=>	MoDVV2FPT0WU
NB5	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13sSGlEPTB;MD6wPVYzPSEQvF2=	MlXaV2FPT0WU
A704	NV72Z5hMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nMWGlEPTB;MD6wPVc1OSEQvF2=	NYnaVXI2W0GQR1XS
SF268	NWP1V\|h[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnpTWM2OD1yLkC5PFI2KM7:TR?=	MoPoV2FPT0WU
UACC-257	M1\RZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnZRWl7UUN3ME2wMlA6QDN\|IN88US=>	MW\TRW5ITVJ?
L-428	M1v6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXlblAyUUN3ME2wMlExOzJizszN	M3r0fnNCVkeHUh?=
ST486	NWH1V4txT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfyTWM2OD1yLkGwOlA3KM7:TR?=	MnuzV2FPT0WU
SK-MM-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DxSGlEPTB;MD6xNFcxQSEQvF2=	MUXTRW5ITVJ?
COR-L279	MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\xNWFrUUN3ME2wMlExQDN{IN88US=>	MVfTRW5ITVJ?
JiyoyeP-2003	Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMUC4OFMh\|ryP	MnvnV2FPT0WU
GT3TKB	NF3sbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LmU2lEPTB;MD6xNFkyQCEQvF2=	MnLpV2FPT0WU
HCE-T	M2rrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMUC5OEDPxE1?	M3nXe3NCVkeHUh?=
SBC-1	NX70N2NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7oTWM2OD1yLkGxNVE6KM7:TR?=	NWjkbo1{W0GQR1XS
KNS-81-FD	NEXPZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\oVGlEPTB;MD6xNVI4OyEQvF2=	M2LLfHNCVkeHUh?=
NCI-H2126	MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMUGzPVQh\|ryP	MoHTV2FPT0WU
EM-2	NXvyeJBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4S0e2lEPTB;MD6xNVUzQSEQvF2=	M32w[nNCVkeHUh?=
JAR	NWL4WHg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NITvTJNKSzVyPUCuNVE2QThizszN	NUnF[XBnW0GQR1XS
NB17	M4iwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIi5WHpKSzVyPUCuNVE3PTJizszN	NV\obJp1W0GQR1XS
LB647-SCLC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4f5fWlEPTB;MD6xNVcxPSEQvF2=	NWrrd4ltW0GQR1XS
CAL-148	MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrSfXRoUUN3ME2wMlEyQCEQvF2=	MoPRV2FPT0WU
K052	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fRemlEPTB;MD6xNVg2OSEQvF2=	NXK2bY41W0GQR1XS
KARPAS-299	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPRcWZKSzVyPUCuNVIzOzNizszN	NEH4UZdUSU6JRWK=
KARPAS-422	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37WRWlEPTB;MD6xNlQ{OiEQvF2=	NUDvWYVMW0GQR1XS
LOXIMVI	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlyxTWM2OD1yLkGyOVE2KM7:TR?=	NHTIVmlUSU6JRWK=
SCC-3	MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPVT4ZLUUN3ME2wMlEzQDVzIN88US=>	M1;qNnNCVkeHUh?=
LU-139	M3LXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHVTIFwUUN3ME2wMlEzQTd3IN88US=>	MXrTRW5ITVJ?
COLO-320-HSR	M4rJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTWTWM2OD1yLkGzNFg3KM7:TR?=	NHfS[nlUSU6JRWK=
ONS-76	NXvETnRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;TTWM2OD1yLkGzNVMh\|ryP	M4rtV3NCVkeHUh?=
U-266	NXT4XWVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LiTWlEPTB;MD6xN\|I1PSEQvF2=	MWDTRW5ITVJ?
HH	NILNSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMUO1N\|Uh\|ryP	MVjTRW5ITVJ?
BB49-HNC	M2\hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\tdnRVUUN3ME2wMlE{PTh5IN88US=>	MkHVV2FPT0WU
NCI-SNU-5	M3PRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmS2TWM2OD1yLkGzOVk3KM7:TR?=	MXzTRW5ITVJ?
C2BBe1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTBwMUO3OFYh\|ryP	Ml65V2FPT0WU
ML-2	M2mybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDHW2VKSzVyPUCuNVM6PTNizszN	M2\ibHNCVkeHUh?=
SCH	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;reIVKSzVyPUCuNVM6PzRizszN	MXfTRW5ITVJ?
NCI-H82	NXrGWmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LKbmlEPTB;MD6xOFExPCEQvF2=	M4\MSnNCVkeHUh?=
MDA-MB-134-VI	MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwMUSyOVIh\|ryP	NECzcG9USU6JRWK=
SK-N-DZ	NU\RSGcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7KVVkxUUN3ME2wMlE1PzF7IN88US=>	NGHPPYtUSU6JRWK=
HL-60	NE\pW\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVWwVHdHUUN3ME2wMlE1QTJizszN	NYP3clBNW0GQR1XS
LB373-MEL-D	M4rWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fU[WlEPTB;MD6xOVU{QSEQvF2=	NHrB[2hUSU6JRWK=
LB831-BLC	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\XUmlEPTB;MD6xOlA4PiEQvF2=	M2\iOXNCVkeHUh?=
SK-NEP-1	MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zONGlEPTB;MD6xOlExOSEQvF2=	M4q3PXNCVkeHUh?=
IMR-5	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVv6[Iw3UUN3ME2wMlE3PDh\|IN88US=>	NHzuR21USU6JRWK=
Calu-6	NHfYe\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnmSGZQUUN3ME2wMlE3PTN5IN88US=>	NFLle\|JUSU6JRWK=
NCI-H1882	MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMU[3Nlgh\|ryP	NYr2WlRQW0GQR1XS
NCI-H446	MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHi4TVVKSzVyPUCuNVY5QTFizszN	NUG1RnBvW0GQR1XS
GI-ME-N	NGLkUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm[1TWM2OD1yLkG4NFIh\|ryP	MmXhV2FPT0WU
MPP-89	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mon5TWM2OD1yLkG4NVIyKM7:TR?=	Ml\ZV2FPT0WU
CGTH-W-1	NXrHdJo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUGyPIFTUUN3ME2wMlE5PDN4IN88US=>	NIG0eJNUSU6JRWK=
MEG-01	M2jxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;DVlNwUUN3ME2wMlE5PjJ6IN88US=>	MlPvV2FPT0WU
NCI-H748	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfJTXJKSzVyPUCuNVg6OTFizszN	MVjTRW5ITVJ?
COLO-829	MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nJOmlEPTB;MD6yNFY4OyEQvF2=	NFruOHVUSU6JRWK=
GOTO	NYrBTY4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMkC3N{DPxE1?	M2PjTnNCVkeHUh?=
EW-3	M2m2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvKc4VJUUN3ME2wMlIyPzF6IN88US=>	MkXXV2FPT0WU
KY821	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP0SW1KSzVyPUCuNlIxPDVizszN	M2fzO3NCVkeHUh?=
CTB-1	NWDB[o9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF6wTJhKSzVyPUCuNlIzOjhizszN	MnuxV2FPT0WU
TALL-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLjc4R6UUN3ME2wMlIzQTJzIN88US=>	NGjONm9USU6JRWK=
NCI-H209	NYnxO3huT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwMkK5OlIh\|ryP	M4nwbXNCVkeHUh?=
IST-MES1	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zFXGlEPTB;MD6yN\|UyKM7:TR?=	MYfTRW5ITVJ?
DMS-114	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjIb4cxUUN3ME2wMlI{QTl\|IN88US=>	NVjLVWxFW0GQR1XS
SNU-C2B	NFPPNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;iV4lpUUN3ME2wMlI1OzF4IN88US=>	M4PUVXNCVkeHUh?=
DG-75	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fMfmlEPTB;MD6yOlE6PSEQvF2=	NFfKUXRUSU6JRWK=
D-336MG	M3KzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[wdpFKUUN3ME2wMlI3PTV5IN88US=>	M1zDTnNCVkeHUh?=
KMOE-2	NVK2T\|I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYq4S\|FpUUN3ME2wMlI4PTN6IN88US=>	MnzQV2FPT0WU
NB1	M2WwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInxWlJKSzVyPUCuNlc6OjZizszN	NUDoS5FEW0GQR1XS
RH-1	M4rrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fRbGlEPTB;MD6yO\|k5QSEQvF2=	MnGxV2FPT0WU
TE-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDzcFlsUUN3ME2wMlI5PDd7IN88US=>	MoW0V2FPT0WU
RPMI-6666	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWS3eWp5UUN3ME2wMlI5QDRizszN	M1\QTHNCVkeHUh?=
TE-9	M2rKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Tsc2lEPTB;MD6yPFk5PSEQvF2=	NHvWW\|FUSU6JRWK=
BT-474	M1jzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnwN4FuUUN3ME2wMlI6OzN2IN88US=>	M1TaSXNCVkeHUh?=
COLO-668	NWPEeHdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMkm0Nlkh\|ryP	M3ftSnNCVkeHUh?=
NCI-H1581	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHueXdZUUN3ME2wMlI6Pjh7IN88US=>	NF;wc3VUSU6JRWK=
MN-60	NWKx[5NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;UTWM2OD1yLkK5PVA2KM7:TR?=	M3u3NHNCVkeHUh?=
L-540	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwM{CwPFEh\|ryP	NF7tWlBUSU6JRWK=
MOLT-13	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXFTWM2OD1yLkOwNVg{KM7:TR?=	NFeySFNUSU6JRWK=
NCI-SNU-16	M36ycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XJOmlEPTB;MD6zNFIxPSEQvF2=	Mnf0V2FPT0WU
NCI-H64	M3TiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHoTWM2OD1yLkOwN\|MyKM7:TR?=	M1npTHNCVkeHUh?=
CP66-MEL	NFPSPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37zbWlEPTB;MD6zNVQyPSEQvF2=	M1K3SnNCVkeHUh?=
NB69	NFSyfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXqU\|VKSzVyPUCuN\|IyQDhizszN	NHLMXHRUSU6JRWK=
NCI-H2196	NW\FNYttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfBZ\|A6UUN3ME2wMlM{ODN4IN88US=>	MUPTRW5ITVJ?
MHH-CALL-2	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XqUWlEPTB;MD6zN\|Q3QCEQvF2=	NYPRXZByW0GQR1XS
HCC2157	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLGTWM2OD1yLkOzPVU1KM7:TR?=	M2ryVnNCVkeHUh?=
LS-1034	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:xU3JTUUN3ME2wMlM3Ozh6IN88US=>	NV3XeFVzW0GQR1XS
BOKU	NEjUOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnrOoRmUUN3ME2wMlM4OTl7IN88US=>	NH[wbnJUSU6JRWK=
GDM-1	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TXc2lEPTB;MD6zO\|I{PCEQvF2=	Ml3pV2FPT0WU
TGW	MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwM{e0OVMh\|ryP	MVjTRW5ITVJ?
SNU-C1	M37GVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwM{iyNVUh\|ryP	NHLVT25USU6JRWK=
LS-513	M3LDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVmxcWNxUUN3ME2wMlM6ODdzIN88US=>	NFTvbHFUSU6JRWK=
NOMO-1	M{HEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:1RZZKSzVyPUCuN\|k6PzFizszN	MlPLV2FPT0WU
MS-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofXTWM2OD1yLkSwNVc4KM7:TR?=	NW\qTpJvW0GQR1XS
EKVX	NFHLbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHNTWM2OD1yLkS0OFYyKM7:TR?=	MUjTRW5ITVJ?
SK-MEL-2	NWLMNoVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfwTWM2OD1yLkS2OEDPxE1?	MXnTRW5ITVJ?
HCC1187	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\SUlVKSzVyPUCuOFY4PjhizszN	MmO3V2FPT0WU
HCC2218	NFS4Z2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHn6U\|VKSzVyPUCuOFczOjdizszN	M1GxfnNCVkeHUh?=
NCI-H187	M4O2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwNEe4OEDPxE1?	NHq3OldUSU6JRWK=
DB	NGr2WIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHzO4I4UUN3ME2wMlUxODV3IN88US=>	MYPTRW5ITVJ?
NCI-H69	M3\iTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwNUCyOFch\|ryP	NIrRSW9USU6JRWK=
NCI-H1694	NHXINpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r1dWlEPTB;MD61NFY6PyEQvF2=	MULTRW5ITVJ?
CA46	M1Lt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXvW29iUUN3ME2wMlUxQTF5IN88US=>	MoH5V2FPT0WU
EHEB	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TZWGlEPTB;MD61NVE6OyEQvF2=	MoPwV2FPT0WU
NCCIT	NGjRZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHU[\|BMUUN3ME2wMlU1OzJzIN88US=>	M3PsZXNCVkeHUh?=
NCI-H720	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DmO2lEPTB;MD61OFk3OiEQvF2=	NIP3fFRUSU6JRWK=
LU-134-A	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XaZ2lEPTB;MD61OVI6PiEQvF2=	NFi3ZY1USU6JRWK=
MC-CAR	NH\lSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DadWlEPTB;MD61OVQ{OSEQvF2=	MX\TRW5ITVJ?
NEC8	MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XHVWlEPTB;MD61OlE4OiEQvF2=	MYDTRW5ITVJ?
NCI-H524	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi0[ZpKSzVyPUCuOVg4PDhizszN	MmXhV2FPT0WU
NCI-H1963	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7KTWM2OD1yLk[yOVgh\|ryP	NGn2dVZUSU6JRWK=
SU-DHL-1	NEnBSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7vTG5KSzVyPUCuOlQ2OjZizszN	MVXTRW5ITVJ?
NCI-H1522	MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\3U2lEPTB;MD62OFg5OyEQvF2=	MoTJV2FPT0WU
NCI-H1155	M2rabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml64TWM2OD1yLk[1N\|Uh\|ryP	M{HSd3NCVkeHUh?=
D-263MG	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3JTWM2OD1yLk[2NVAyKM7:TR?=	NXfEPJRJW0GQR1XS
TE-6	M{TPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHCVoVnUUN3ME2wMlY5OTB2IN88US=>	NVzNXnVjW0GQR1XS
NCI-H1417	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInPT4NKSzVyPUCuOlk4OTFizszN	Mn\hV2FPT0WU
NCI-H510A	M2KyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwN{eyN\|Yh\|ryP	NX\DSHp5W0GQR1XS
KARPAS-45	NGDnS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHkSI9KSzVyPUCuO\|gzOzVizszN	M4PNbHNCVkeHUh?=
IST-SL1	NUC4Z5l7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\hXVJoUUN3ME2wMlg2QDJ3IN88US=>	M3zQbXNCVkeHUh?=
COLO-824	NH3GS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTqcFhIUUN3ME2wMlg4QDN3IN88US=>	NXPGdmtNW0GQR1XS
NCI-H526	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLKTXpKSzVyPUCuPVA6PThizszN	NX3FUG84W0GQR1XS
NCI-H719	M3r5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPJTWM2OD1yLkm2OlU4KM7:TR?=	MX\TRW5ITVJ?
SF539	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TwdGlEPTB;MD65PFM6PiEQvF2=	MnPiV2FPT0WU
NKM-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXOwTZptUUN3ME2wMlk5PjZ\|IN88US=>	NUGzb4NLW0GQR1XS
A253	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm5eVdqUUN3ME2wMlk5QDh3IN88US=>	MnnSV2FPT0WU
TE-441-T	NUXOVmJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3XTWM2OD1zLkC0N\|Uh\|ryP	MoXjV2FPT0WU
COR-L88	NYPSRYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1njSWlEPTB;MT6xNVM2PCEQvF2=	M3TMV3NCVkeHUh?=
CPC-N	NXLhPGpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwMUW4PFgh\|ryP	NGntW4lUSU6JRWK=
NCI-H2107	MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTKTWM2OD1zLkG3NlYyKM7:TR?=	NFnPUmpUSU6JRWK=
ECC4	NU\1RWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVflfJA1UUN3ME2xMlE5Pjl\|IN88US=>	NWPHWWxZW0GQR1XS
NCI-H2141	M3u1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTFwMUmyPVkh\|ryP	MlPTV2FPT0WU
NCI-H1770	M17tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Cyd2lEPTB;MT6zNlkzQCEQvF2=	NUPQb5JXW0GQR1XS
NCI-SNU-1	M4Lk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3zcFhzUUN3ME2xMlM{ODRizszN	MWnTRW5ITVJ?
LU-165	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\USpNKSzVyPUGuOFU1PjdizszN	MmniV2FPT0WU
Raji	NUCyeldqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXGRZZKSzVyPUGuOFczPTlizszN	MnTPV2FPT0WU
EW-24	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;L[YxKSzVyPUGuOVQ3OTlizszN	MV;TRW5ITVJ?
KP-N-RT-BM-1	M1LRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vFSmlEPTB;MT61OlU2OSEQvF2=	MUPTRW5ITVJ?
SK-MEL-1	M{nlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHIcGNrUUN3ME2xMlY1QDd5IN88US=>	MmfrV2FPT0WU
SCLC-21H	NUXGb4hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljDTWM2OD1zLk[2OlUyKM7:TR?=	MW\TRW5ITVJ?
SIMA	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTFwNkiyN\|Mh\|ryP	Mo\pV2FPT0WU
NCI-H1304	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\KTWM2OD1zLkewO\|Y2KM7:TR?=	MVjTRW5ITVJ?
REH	NFv0TWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPvfIRFUUN3ME2xMlcyODd6IN88US=>	NVfac5FlW0GQR1XS
KP-N-YS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTFwOUO1OVEh\|ryP	NFXJOldUSU6JRWK=
DMS-153	NGH4bmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVezSlBoUUN3ME2xMlk4PTlizszN	NWTpeohTW0GQR1XS
NB10	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjTbpVkUUN3ME2yMlIxQDd6IN88US=>	MlPYV2FPT0WU
NCI-H345	MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTJwNkG5NFUh\|ryP	NUC4Sm54W0GQR1XS
SK-N-FI	NGTr[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TB[2lEPTB;Mj63OVM5OSEQvF2=	NIHQZXdUSU6JRWK=
NCI-H1092	NXq3NVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;jTWM2OD1{Lkm1N\|k1KM7:TR?=	NXe5U\|JuW0GQR1XS
KM-H2	NF6zRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTNwNkWzPVYh\|ryP	MlLjV2FPT0WU
KG-1	NEDqUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTNwN{G2PFgh\|ryP	MnqxV2FPT0WU
D-283MED	MlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljKTWM2OD1\|Lke1PFch\|ryP	M2fTNHNCVkeHUh?=
LU-65	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonQTWM2OD12LkGxOFg2KM7:TR?=	MXfTRW5ITVJ?
MSTO-211H	NF\S[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUf2TWF{UUN3ME20MlE5QDl6IN88US=>	MYjTRW5ITVJ?
NCI-H2081	NEHtTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4m5fmlEPTB;ND6yPVE4PCEQvF2=	NUj1b\|lqW0GQR1XS
D-247MG	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XxSWlEPTB;ND60N\|E6OSEQvF2=	NIHobnZUSU6JRWK=
P31-FUJ	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzPU\|d4UUN3ME20MlQ2ODF7IN88US=>	NXT4e\|BqW0GQR1XS
DMS-79	NX\MWZh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLnTWM2OD12LkmzNVg{KM7:TR?=	NXzUR3lCW0GQR1XS
KASUMI-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTRwOUe1NFkh\|ryP	M3XmdHNCVkeHUh?=
JVM-3	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnxTWM2OD13LkK1NFE1KM7:TR?=	NGLFZlZUSU6JRWK=
LAN-6	NEnoN\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTVwNUG3N\|Yh\|ryP	NHvtSVlUSU6JRWK=
DJM-1	NE\BT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHW2eIdKSzVyPUWuOVYxOjlizszN	MUTTRW5ITVJ?
JVM-2	NGG0bIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rR[mlEPTB;NT62O\|A6OiEQvF2=	MoS5V2FPT0WU
U-87-MG	M4H5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTVwOEm5OlQh\|ryP	NE\zdYxUSU6JRWK=
SHP-77	M1PYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPHT2dKSzVyPUWuPVQ6OjhizszN	M1\Rd3NCVkeHUh?=
RPMI-8866	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTZwMkewNVMh\|ryP	M1LBeXNCVkeHUh?=
ES7	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XsWGlEPTB;Nj6zPVkzPCEQvF2=	M3qwU3NCVkeHUh?=
WSU-NHL	NVTHe5gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVu3W2NKUUN3ME22MlUyPjB7IN88US=>	M1LzU3NCVkeHUh?=
CAS-1	MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGWxfYhKSzVyPUeuNFk4PDlizszN	M1Pt[XNCVkeHUh?=
MHH-NB-11	MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4noWmlEPTB;OD6yN\|E2OiEQvF2=	NF60N5dUSU6JRWK=
ES5	NYTNdHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvWXId6UUN3ME25MlUzOjh4IN88US=>	NIraRo9USU6JRWK=
HDLM-2	NFK1ZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fqN2lEPTB;OT65OVkxOiEQvF2=	NEnqO49USU6JRWK=
NCI-H2171	NE\UTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\Dd5hoUUN3ME2xNE42QTJ5IN88US=>	MXnTRW5ITVJ?
LNCaP-Clone-FGC	NE\nUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzV[IVFUUN3ME2xNU4{PzF6IN88US=>	MojLV2FPT0WU
NCI-H1395	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfMTWM2OD1zMj6yOlk6KM7:TR?=	MlzBV2FPT0WU
NCI-H1436	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLrcplDUUN3ME2xN{4{OTl3IN88US=>	NUPMSo9wW0GQR1XS
RCC10RGB	NGP2[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfwPZpKSzVyPUGzMlMzOjFizszN	MXjTRW5ITVJ?
SW684	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTF\|Lkm3PVch\|ryP	MoPmV2FPT0WU
NCI-H1650	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTF3LkC0OFch\|ryP	NXXwPFM3W0GQR1XS
EW-13	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTF3LkKwNlEh\|ryP	MlH0V2FPT0WU
EC-GI-10	NWPue4pYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWq3bGVGUUN3ME2xOU45PjR2IN88US=>	Mn3QV2FPT0WU
CHP-126	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nJZWlEPTB;MUeuNVkyQCEQvF2=	Mn\uV2FPT0WU
NCI-H226	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nqeWlEPTB;MUiuNFQxOyEQvF2=	MVvTRW5ITVJ?
NCI-H1838	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTJyLkG4OFgh\|ryP	M4LYVXNCVkeHUh?=
EW-11	NVHnXnpFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTJ2LkK3NVgh\|ryP	MmPIV2FPT0WU
EB2	M1TIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHmTWM2OD1\|MT61N\|E5KM7:TR?=	NITtNW9USU6JRWK=
D-502MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXkTWM2OD12Mz65NlI6KM7:TR?=	NXHaW3VnW0GQR1XS
U-698-M	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTR6Lki2O\|Eh\|ryP	MlHNV2FPT0WU
ES3	M4XKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfIPFZvUUN3ME20PU4{QDl\|IN88US=>	MoL5V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo

Torin1 is efficacious at a dose of 20 mg/kg in a U87MG xenograft model and demonstrates good pharmacodynamic inhibition of downstream effectors of mTOR in tumor and peripheral tissues. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand mTORC1 and mTORC2 in Vitro Kinase Assays: To produce soluble mTORC1, HEK-293T cell lines that stably express N-terminally FLAG-tagged Raptor are generated using vesicular stomatitis virus G-pseudotyped MSCV retrovirus. For mTORC2, similar HeLa cells that stably express N-terminally FLAG-tagged Protor-1 are generated. Both complexes are purified by lysing cells in 50 mm HEPES, pH 7.4, 10 mm sodium pyrophosphate, 10 mm sodium β-glycerophosphate, 100 mm NaCl, 2 mm EDTA, 0.3% CHAPS. Cells are lysed at 4 °C for 30 min, and the insoluble fraction is removed by microcentrifugation at 13,000 rpm for 10 min. Supernatants are incubated with FLAG-M2 monoclonal antibody-agarose for 1 h and then washed three times with lysis buffer and once with lysis buffer containing a final concentration of 0.5 M NaCl. Purified mTORC1 is eluted with 100 μg/mL 3×FLAG peptide in 50 mm HEPES, pH 7.4, 100 mm NaCl. Eluate can be aliquoted and stored at -80 °C. Substrates S6K1 and Akt1 are purified. Kinase assays are performed for 20 min at 30 °C in a final volume of 20 μL consisting of the kinase buffer (25 mm HEPES, pH 7.4, 50 mm KCl, 10 mm MgCl₂, 500 μm ATP) and 150 ng of inactive S6K1 or Akt1 as substrates. Reactions are stopped by the addition of 80 μL of sample buffer and boiled for 5 min. Samples are subsequently analyzed by SDS-PAGE and immunoblotting.
Cell Research:^[1]	+ Expand Cell lines: MEFs Concentrations: ~250 nM Incubation Time: 4 days Method: Cell viability is assessed with the CellTiter-Glo Luminescent Cell Viability Assay. On Day 0, 96-well plates are seeded with 500 cells per well and grown overnight. On Day 1, cells are treated with the appropriate compounds and subsequently analyzed on Days 3-5. For analysis, plates are incubated for 60 min at room temperature; 50 μL of CellTiter-Glo reagent is added to each well, and plates are mixed on an orbital shaker for 12 min. Luminescence is quantified on a standard plate luminometer. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: U87MG xenograft model Formulation: Torin1 powder is first dissolved at 25 mg/mL in 100% N-methyl-2-pyrrolidone and subsequently diluted 1:4 with sterile 50% PEG400 to a final concentration of 5 mg/mL Dosages: 20 mg/kg Administration: Administered via i.p. once daily (Only for Reference)

References

[4] Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176.

+ Expand

Solubility (25°C)

In vitro	DMSO	2 mg/mL (3.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 20% NMP+50% PEG 400 For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Torin 1 SDF

Molecular Weight	607.62
Formula	C₃₅H₂₈F₃N₅O₂
CAS No.	1222998-36-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to re-constitute the inhibitor for i.p. administration?
Answer:
S2827 Torin 1 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 0.25 mg/ml clearly, and in 10% DMSO/corn oil at 0.5 mg/ml, it is also a clear solution.

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Selective mTOR inhibitor

Rapamycin (Sirolimus) : mTORC1-selective, IC50=~0.1 nM.
Most Potent mTOR Inhibitor

Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.
FDA-approved mTOR Inhibitor

Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).
Newest mTOR Inhibitor

XL388 ^New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.
AZD8055

AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

Features:First drug to inhibit both types of mTOR protein.
Temsirolimus (CCI-779, NSC 683864)

Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.
Sapanisertib (INK 128, MLN0128)

Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Tacrolimus (FK506)

Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.
KU-0063794

KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Choose Your Country or Region

By Signaling Pathways

By product type

Torin 1